18:31 , Nov 30, 2018 |  BC Week In Review  |  Company News

Ascletis adds HBV therapy to portfolio through Roche partnership

With one marketed HCV therapy in China and another under review, Ascletis Pharma Inc. (HKSE:1672) extended its commercial viral hepatitis footprint in the country on Nov. 20 with exclusive rights to marketed HBV drug Pegasys...
22:05 , Nov 20, 2018 |  BC Extra  |  Company News

Ascletis adds marketed HBV drug from Roche to Chinese portfolio

With one marketed HCV therapy in China and another under review, Ascletis Pharma Inc. (HKSE:1672) extended its commercial viral hepatitis footprint in the country on Tuesday with exclusive rights to marketed HBV drug Pegasys peginterferon...
18:52 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

Replicor HBV combo leads to functional control

Replicor Inc. (Montreal, Quebec) reported interim data from the Moldovan Phase II REP 401 trial to treat non-cirrhotic, hepatitis B e antigen (HBeAg)-negative, chronic HBV infection showing that REP 2139-Mg in combination with Viread tenofovir...
21:01 , Oct 23, 2017 |  BC Extra  |  Clinical News

Replicor HBV combo leads to functional control

Replicor Inc. (Montreal, Quebec) reported interim data from the Moldovan Phase II REP 401 trial to treat chronic HBV infection showing that REP 2139-Mg in combination with Viread tenofovir disoproxil fumarate and Pegasys peginterferon alfa-2a...
00:42 , Aug 12, 2017 |  BioCentury  |  Product Development

HBV test kitchen

Early results for HBV monotherapies are pointing the way toward combinations that could deliver a functional cure. What remains unknown is how many components, and which ones, will prove necessary to eliminate remnants of the...
17:35 , Feb 3, 2017 |  BC Week In Review  |  Clinical News

REP 2165-Mg: Preliminary Ph II REP 401 data

Preliminary data from 40 treatment-naïve, non-cirrhotic patients with HBeAg-negative chronic HBV infection in the open-label Phase II REP 401 trial showed that once-weekly 250 mg IV REP 2139-Mg and REP 2165-Mg plus Viread tenofovir and...
17:35 , Feb 3, 2017 |  BC Week In Review  |  Clinical News

REP 2139-Mg: Preliminary Ph II REP 401 data

Preliminary data from 40 treatment-naïve, non-cirrhotic patients with HBeAg-negative chronic HBV infection in the open-label Phase II REP 401 trial showed that once-weekly 250 mg IV REP 2139-Mg and REP 2165-Mg plus Viread tenofovir and...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Clinical News

REP 2139-Mg: Phase IIb started

Replicor began the open-label, Moldovan Phase IIb REP 401 trial of REP 2139-Mg or REP 2165-Mg in about 60 Caucasian patients who have received Viread tenofovir disoproxil fumarate for 24 weeks. All patients will continue...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Clinical News

REP 2165-Mg: Phase IIb started

Replicor began the open-label, Moldovan Phase IIb REP 401 trial of REP 2139-Mg or REP 2165-Mg in about 60 Caucasian patients who have received Viread tenofovir disoproxil fumarate for 24 weeks. All patients will continue...
07:00 , May 11, 2015 |  BC Week In Review  |  Clinical News

REP 2139-Ca: Interim Phase II data

Interim data from the open-label, Moldovian Phase II REP 301 trial in patients with chronic HBV and HDV co-infection showed that once-weekly IV REP 2139-CA as monotherapy was well tolerated and led to rapid and...